LinkedIn
WebsiteIntroduction
Clearmind Medicine Inc. (NASDAQ: CMND) is a Vancouver-based biotechnology company founded in 2021. The firm develops psychedelics-based treatments for binge behaviour and mental health conditions, with a lead candidate, MEAI (5-Methoxy-2-aminoindane), which targets alcohol use disorder, binge eating, and depression.
Corporate Structure
With a workforce of 11–50 employees, Clearmind Medicine has assembled a team with experience in drug development and regulatory affairs. Dr. Adi Zuloff-Shani serves as a Biomedical Research and Development Executive, contributing over 20 years of strategic and operational leadership in healthcare environments. The company focuses on intellectual property protection and clinical expertise in psychedelics therapeutics.
Psychedelics by Pretty Drugthings
Recent Developments and News
On September 19, 2025, Clearmind filed a Form 6-K with the U.S. Securities and Exchange Commission reporting a $10 million Securities Purchase Agreement aimed at exploring strategic opportunities. Two days earlier, on September 17, 2025, the company executed securities purchase agreements to issue convertible promissory notes totaling up to $10 million, with initial closings of $555,556 and $1,944,444, to be used for working capital, corporate purposes, and potential acquisitions. A Post-Effective Amendment No. 7 was filed on September 15, 2025, updating the registration statement for the resale of up to 1.5 million common shares issuable upon warrant exercise. On the NASDAQ exchange on September 19, 2025, CMND shares traded 9,063,460 shares and closed at $1.32, up 32% from the prior close of $1.00. In a company webinar, Mark Haden discussed the evolving landscape of psychedelic research and its potential implications for mental health care.
Financial and Strategic Analysis
Clearmind Medicine’s market capitalization is approximately $5.38 million. For the trailing twelve months, the company reported a net loss of $4.05 million and a levered free cash flow deficit of $4.13 million. As of the most recent quarter, total cash on the balance sheet was $3.5 million, with a debt-to-equity ratio of 2.67%. The convertible note agreements carry interest rates starting at 4%, increasing to 14% upon default, and allow further issuances in three-month intervals, subject to trading volume thresholds. Proceeds from these agreements are intended to support the MEAI program, advancing operational needs and evaluating acquisitions to expand the pipeline.
Market Position and Industry Context
According to company-sourced research, the global substance abuse market is valued at $193 billion and the alcohol abuse segment at $249 billion. Clearmind operates in the psychedelics therapeutics sector alongside developers of MDMA, psilocybin, and ibogaine derivatives. By developing MEAI as a potential alcohol alternative and treatment for alcohol use disorder, the company aims to address an underserved area that has limited approved therapies and increased interest in non-alcoholic options.
tl;dr
On September 19, 2025, CMND shares increased by 32% to $1.32 following the announcement of a $10 million Securities Purchase Agreement in a Form 6-K. On September 17, convertible promissory notes for up to $10 million were arranged, and on September 15, a post-effective amendment updated the resale registration for warrants. The financing is intended to advance MEAI development, fund operations, and support acquisitions. Future developments include additional note closings and registration statement effectiveness.
